NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders

NMD Pharma secures one of the largest Series A financings in Scandinavia from a top tier international syndicate to support development through clinical proof-of-concept of two programs that target orphan neurological disorders and in-hospital critical care indications.Århus, Denmark, March [TBD], 2018 - NMD Pharma A/S, a private biotech company focused on developing novel first in class therapies for severe neuromuscular disorders today announced a transformative €38 million Series A financing led by new investor INKEF Capital, together with new investor Roche Venture Fund and existing